65 and older, any sex, with Acute Myeloid Leukemia (AML). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Complete Remission RatePrimary· 6 months
Complete remission rate is defined as number of subjects with complete remission according to the IWG criteria, which is defined by presence of \<5 percent of blasts in the bone marrow, absence of blasts with Auer rods, absence of extramedullary disease, absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions.
Group
Value
95% CI
Arm A: Pacritinib and Decitiabine
0
Arm B: Pacritinib and Cytarabine
0
Overall SurvivalSecondary· 2 years
Survival following treatment to the date of death
Group
Value
95% CI
Arm A: Pacritinib and Decitiabine
3
Arm B: Pacritinib and Cytarabine
3
Overall Remission RateSecondary· 6 months
Overall remission rate is defined as number of subjects with complete remission (CR), Complete Remission with incomplete platelet recovery (CRp), Complete Remission with Incomplete Blood Count Recovery (CRi), Partial Remission (PR) according to the IWG criteria. CRi is defined as All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL)), PR is defined as relevant in the setting of phase I and II clinical trials only; all hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25 percent; and decrease of pretr
Group
Value
95% CI
Arm A: Pacritinib and Decitiabine
0
Arm B: Pacritinib and Cytarabine
0
Relapse-free SurvivalSecondary· From date of complete remission until either AML relapse or death from any cause, whichever came first, assessed throughout the study period up to 2 years
Time from complete remission documentation to either AML relapse or death from any cause.
Group
Value
95% CI
Arm A: Pacritinib and Decitiabine
NA
NA – NA
Arm B: Pacritinib and Cytarabine
NA
NA – NA
Event-free SurvivalSecondary· Time from entry on study until time at which there is treatment failure, AML relapse, or death from any cause, assessed throughout the study period up to 2 years
Time from entry on study until time at which there is treatment failure, AML relapse, or death from any cause
Group
Value
95% CI
Arm A: Pacritinib and Decitiabine
2.5
2 – 4
Arm B: Pacritinib and Cytarabine
3
1 – 5
Time to Complete ResponseSecondary· From entry on study until complete remission, assessed throughout the study period up to 2 years
Time from entry on study until documentation of complete remission (CR)
Group
Value
95% CI
Arm A: Pacritinib and Decitiabine
NA
NA – NA
Arm B: Pacritinib and Cytarabine
NA
NA – NA
Remission DurationSecondary· time from complete remission to AML relapse, assessed throughout the study period up to 2 years.
Time from CR documentation to AML relapse
Group
Value
95% CI
Arm A: Pacritinib and Decitiabine
NA
NA – NA
Arm B: Pacritinib and Cytarabine
NA
NA – NA
Adverse events — posted to ClinicalTrials.gov
Time frame: 2 years, 4 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Arm A: Pacritinib and Decitiabine
Serious: 9/9 (100%)
Deaths: 9/9
Arm B: Pacritinib and Cytarabine
Serious: 4/4 (100%)
Deaths: 4/4
Serious adverse events (15 terms)
Reaction
System
Arm A: Pacritinib and Deci…
Arm B: Pacritinib and Cyta…
neutropenic fever
Blood and lymphatic system disorders
—
—
dizziness
Nervous system disorders
—
—
Dizziness and right shoulder pain
Nervous system disorders
—
—
fever
General disorders
—
—
presyncope
Nervous system disorders
—
—
failure to thrive
General disorders
—
—
anxiety
Psychiatric disorders
—
—
congestive heart failure
Cardiac disorders
—
—
cardiopulmonary arrest
Cardiac disorders
—
—
dehydration/diarrhea
Gastrointestinal disorders
—
—
chest pain
Cardiac disorders
—
—
fall
General disorders
—
—
acute respiratory failure
Respiratory, thoracic and mediastinal disorders
—
—
hematuria
Renal and urinary disorders
—
—
oral ulceration
General disorders
—
—
Other adverse events (181 terms — click to expand)
The purpose of this study is to see if a medicine called pacritinib is both safe and effective as a study intervention for patients with AML in combination with either decitabine or cytarabine. Pacritinib is an experimental drug that is being studied to treat acute myeloid leukemia (AML). Decitabine and cytarabine are both FDA approved drugs that are used in treatment of AML. Pacritinib is being tested in clinical trials and has not been submitted to the U.S. Food and Drug Administration (FDA) for approval for any indications. Pacritinib is a drug that is designed to slow down the growth of leukemic cells.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym
· Phase 1
· recruiting
NCT07447817 — Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
· Phase 2
· not yet recruiting
NCT07148947 — Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant
· Phase 2
· recruiting
NCT07226713 — Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatmen
· Phase 2
· not yet recruiting
NCT06986174 — A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi
· Phase 2
· recruiting
Other recruiting trials for Acute Myeloid Leukemia (AML)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 15 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02532010.